BioCentury
ARTICLE | Product Development

Phase II data show Novo’s semaglutide leads the pack on NASH resolution

May 6, 2020 11:04 PM UTC

Novo Nordisk disclosed top-line Phase II data in NASH for semaglutide that puts the GLP-1 agonist in pole position with respect to mechanisms addressing NASH resolution.

The readout came as Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) announced strong growth in 1Q20 due to COVID-19-related stockpiling. ...

BCIQ Company Profiles

Novo Nordisk A/S